Literature DB >> 22984115

Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.

Gang Sun1, Tao Luo, Chongguang Yang, Xinran Dong, Jing Li, Yongqiang Zhu, Huajun Zheng, Weidong Tian, Shengyue Wang, Clifton E Barry, Jian Mei, Qian Gao.   

Abstract

BACKGROUND: Drug-resistant tuberculosis poses a growing challenge to global public health. However, the diversity and dynamics of the bacterial population during acquisition of drug resistance have yet to be carefully examined.
METHODS: Whole-genome sequencing was performed on 7 serial Mycobacterium tuberculosis (M. tuberculosis) populations from 3 patients during different stages in the development of drug resistance. The population diversity was assessed by the number and frequencies of unfixed mutations in each sample.
RESULTS: For each bacterial population, 8-41 unfixed mutations were monitored by the fraction of single-nucleotide polymorphisms at specific loci. Among them, as many as 4 to 5 resistance-conferring mutations were transiently detected in the same single sputum, but ultimately only a single type of mutant was fixed. In addition, we identified 14 potential compensatory mutations that occurred during or after the emergence of resistance-conferring mutations.
CONCLUSIONS: M. tuberculosis population within patients exhibited considerable genetic diversity, which underwent selections for most fit resistant mutant. These findings have important implications and emphasize the need for early diagnosis of tuberculosis to decrease the chance of evolving highly fit drug-resistant strains.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22984115      PMCID: PMC3488197          DOI: 10.1093/infdis/jis601

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  Fitness cost of chromosomal drug resistance-conferring mutations.

Authors:  Peter Sander; Burkhard Springer; Therdsak Prammananan; Antje Sturmfels; Martin Kappler; Michel Pletschette; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

3.  Fitness of antibiotic-resistant microorganisms and compensatory mutations.

Authors:  E C Böttger; B Springer; M Pletschette; P Sander
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

4.  The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan
Journal:  Science       Date:  2006-06-30       Impact factor: 47.728

5.  Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis.

Authors:  M L Joloba; J L Johnson; A Namale; A Morrissey; A E Assegghai; R D Mugerwa; J J Ellner; K D Eisenach
Journal:  Int J Tuberc Lung Dis       Date:  2000-06       Impact factor: 2.373

Review 6.  Tuberculosis: drug resistance, fitness, and strategies for global control.

Authors:  Erik C Böttger; Burkhard Springer
Journal:  Eur J Pediatr       Date:  2007-11-07       Impact factor: 3.183

7.  Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH.

Authors:  Claire Jenkins; Joanna Bacon; Jon Allnutt; Kim A Hatch; Alpana Bose; Denise M O'Sullivan; Catherine Arnold; Stephen H Gillespie; Timothy D McHugh
Journal:  J Antimicrob Chemother       Date:  2009-04-15       Impact factor: 5.790

8.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

9.  Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria.

Authors:  Omita A Trivedi; Pooja Arora; Vijayalakshmi Sridharan; Rashmi Tickoo; Debasisa Mohanty; Rajesh S Gokhale
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

10.  Dynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatment.

Authors:  Solomon H Mariam; Jim Werngren; Joakim Aronsson; Sven Hoffner; Dan I Andersson
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

View more
  82 in total

1.  High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Brandon Eilertson; Fernanda Maruri; Amondrea Blackman; Miguel Herrera; David C Samuels; Timothy R Sterling
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance.

Authors:  Shaheed V Omar; Remco P H Peters; Nabila Ismail; Nazir A Ismail
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Whole genome sequence analysis of multidrug-resistant Mycobacterium tuberculosis Beijing isolates from an outbreak in Thailand.

Authors:  Sanjib Mani Regmi; Angkana Chaiprasert; Supasak Kulawonganunchai; Sissades Tongsima; Olabisi Oluwabukola Coker; Therdsak Prammananan; Wasna Viratyosin; Iyarit Thaipisuttikul
Journal:  Mol Genet Genomics       Date:  2015-04-24       Impact factor: 3.291

4.  Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.

Authors:  John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

Review 5.  Diversity and evolution of Mycobacterium tuberculosis: moving to whole-genome-based approaches.

Authors:  Stefan Niemann; Philip Supply
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-04       Impact factor: 6.915

6.  Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis.

Authors:  Tami D Lieberman; Douglas Wilson; Reshma Misra; Lealia L Xiong; Prashini Moodley; Ted Cohen; Roy Kishony
Journal:  Nat Med       Date:  2016-10-31       Impact factor: 53.440

7.  Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

Authors:  Melisa Willby; R David Sikes; Seidu Malik; Beverly Metchock; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

8.  Acetylome analysis reveals diverse functions of lysine acetylation in Mycobacterium tuberculosis.

Authors:  Fengying Liu; Mingkun Yang; Xude Wang; Shanshan Yang; Jing Gu; Jie Zhou; Xian-En Zhang; Jiaoyu Deng; Feng Ge
Journal:  Mol Cell Proteomics       Date:  2014-09-01       Impact factor: 5.911

9.  Genetic and phenotypic characterizations of drug-resistant Mycobacterium tuberculosis isolates in Cheonan, Korea.

Authors:  Jae-Sik Jeon; Jae Kyung Kim; Qute Choi; Jong Wan Kim
Journal:  J Clin Lab Anal       Date:  2018-02-03       Impact factor: 2.352

10.  High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.

Authors:  Helen E Jenkins; Valeriu Crudu; Viorel Soltan; Ana Ciobanu; Liliana Domente; Ted Cohen
Journal:  Eur Respir J       Date:  2014-02-20       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.